Dr. Deepak Dabkaraspoke at the Choosing Wisely Meeting & BMC Conclave on the topic of triple therapy for metastatic hormone-sensitive prostate cancer. He explored the necessity of this approach and its historical context. Originally, androgen deprivation therapy (ADT) was the only treatment option, which often led to castration-resistant prostate cancer. Since 2004, new therapeutic agents have emerged, significantly improving survival rates. Key clinical trials demonstrated that chemotherapy can enhance outcomes, particularly in patients with high-volume disease. Dr. Dabkara emphasised the importance of tailoring therapy to patients based on their specific disease characteristics.